Non Small Cell Lung Cancer

Arrow In this section

Introduction

EGFR is a protein found at high levels in many types of cancers, particularly non-small cell lung cancer (NSCLC). Activating mutations in the EGFR gene are present in a proportion of NSCLC tumours. Tumours with mutated EGFR show a higher likelihood of response to treatment with EGFR tyrosine kinase inhibitor drugs e.g. Iressa (Gefitinib).

Please refer to the National Genomic Test Directory for Cancer here.

Reporting times

Targeted EGFR (Salvage pathway) 7 calendar days

T790M targeted test 7 calendar days

NSCLC panel 14 calendar days

Please refer to our Sample Requirements section before sending any samples to us for testing.